Saltar al contenido

Novo Says Women Lost 25% on CagriSema in Trial Analysis, With Differences by Menopause Stage

22 de octubre de 2026 · 15 min

Notas del episodio

Novo Nordisk says women in its phase 3 REDEFINE 1 trial lost 25.0% of their body weight on average after 68 weeks on its investigational weekly injection CagriSema (cagrilintide plus semaglutide), compared with 3.0% on placebo, in a post hoc analysis presented at The Menopause Society 2026 Annual Meeting in San Diego. A second analysis grouped 1,902 women by menopausal stage: average weight loss was 26.7% in premenopausal, 24.8% in perimenopausal and 23.1% in postmenopausal women, versus about 2% on placebo. Both figures use the efficacy estimand, which assumes everyone stayed on treatment, and menopause status was assigned after the fact. Novo calls the findings hypothesis-generating. We cover what the numbers do and don't show, how the full trial population compared (22.7%), how the results line up with earlier tirzepatide analyses in women, the trial's side-effect and discontinuation rates, and where CagriSema stands: not approved, with an FDA decision expected in the fourth quarter of 2026. Sources: - Novo Nordisk press release (Oct 20, 2026): https://www.novonordisk-us.com/media/press-releases/cagrisema-redefine1-weight-loss-women-menopause.html - CNBC: https://www.cnbc.com/2026/10/20/novo-cagrisema-women-weight-loss-analysis.html - BioSpace: https://www.biospace.com/drug-development/novos-cagrisema-achieves-25-weight-loss-in-women-driven-by-younger-patients - Reuters, via ETPharma: https://pharma.economictimes.indiatimes.com/news/research-and-development/novos-cagrisema-helped-women-lose-25-of-weight-on-average-analysis-shows/135085769 Cover: original editorial image made for this episode; the pen shown is generic, not a real product. This show is for information only and is not medical advice. Always talk to your doctor before starting, stopping, or changing any medication. More at glp1newspaper.com

Todos los episodios de GLP-1 Newspaper: Daily Ozempic, Zepbound & Weight-Loss Drug News

Ajustes

Visualización

Idioma

Determina qué emisoras ves primero en la página de inicio.

Historial

Las emisoras y episodios escuchados recientemente y tus últimas búsquedas solo se guardan en este navegador.

Avisos

Un breve aviso cuando un pódcast que sigues tiene un episodio nuevo. Puedes desactivar pódcast concretos con la campana de su página.

Cuenta

Guarda tus favoritos: en la app y en la web.

Atajos de teclado

/
Abrir búsqueda
Espacio
Reproducir o pausar
← →
En el reproductor: 15 s atrás, 30 s adelante (episodios) · en una fila: siguiente tarjeta
↑ ↓
En una fila: destino dentro de la tarjeta
Inicio / Fin
En una fila: primera o última tarjeta
Esc
Cerrar ventana o menú
?
Este resumen
Reproduciendo ahora

Ir a la emisora

A continuación

    Añade episodios con «A continuación»: sonarán después del episodio actual.